WATCH | Primary results and secondary analysis of the Oceanic-Stroke trial
Sponsored by Bayer
Qualifying ischemic stroke subtypes and response to asundexian: Prespecified secondary analysis of the OCEANIC-STROKE trial
Factor XI (FXI) deficiency has been associated with a reduced risk of ischemic stroke without a corresponding increase in intracerebral hemorrhage. However, Mendelian randomization studies and phase 2 trials of FXI inhibition for secondary stroke prevention have suggested differing magnitudes of association according to ischemic stroke subtypes.
In this prespecified secondary analysis, we evaluated whether the treatment effect and safety of asundexian, an oral FXIa inhibitor, in combination with antiplatelet therapy for secondary stroke prevention, are consistent across qualifying ischemic stroke subtypes in OCEANIC-STROKE participants.
This presentation is not part of the official International Stroke Conference 2026 as planned by the American Heart Association & American Stroke Association Committee on International Stroke Programming. The American Heart Association does not endorse any commercial products or programs.
Factor XIa Inhibition with asundexian in acute non-cardioembolic stroke or high-risk transient ischemic attack: Primary results of the OCEANIC-STROKE trial.
Genetic Factor XI (FXI) deficiency is associated with a reduced risk for ischemic stroke without an increase in intracerebral hemorrhage (ICH). Asundexian is an oral FXIa inhibitor with the potential to safely decrease ischemic stroke recurrence based on exploratory phase 2 trial analyses. We aimed to determine efficacy and safety when combined with antiplatelets for the secondary prevention of ischemic stroke.
This presentation is not part of the official International Stroke Conference 2026 as planned by the American Heart Association & American Stroke Association Committee on International Stroke Programming. The American Heart Association does not endorse any commercial products or programs.
